EUVIMEDEUVIMED entdecken
Crossref

Serum-Soluble Human Leukocyte Antigen-G Serves as a Biomarker for Early Gastric Cancer Screening among the Elderly People

Shuangzhen Bao, Xinying Wang, Jiangang Zhao

Digestive Diseases · 2025

DOI: 10.1159/000547447 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases, 2025. Verfasst von Shuangzhen Bao und 2 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery Department, Hengshui People's Hospital, Hengshui, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Early Detection of Cancer, Biomarkers, Tumor, HLA-G Antigens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Gastric cancer is a major cause of gastrointestinal cancer deaths, and early detection is key to improving survival. Current diagnostic methods have limitations, highlighting the need for new biomarkers. Our study aimed to explore the potential of serum-soluble human leukocyte antigen-G (sHLA-G), pepsinogen I/pepsinogen II (PGI/PGII) ratio (PGR), and gastrin-17 (G17) as markers for diagnosing and monitoring gastric cancer progression.

Methods

A retrospective study was conducted to analyze serum levels of sHLA-G, PGR, and G17. These levels were compared among various gastric conditions, including chronic non-atrophic gastritis, chronic atrophic gastritis, precancerous lesions, and gastric cancer. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic performance of these biomarkers.

Results

This study included 429 elderly patients who underwent gastric examination. Results showed that serum levels of sHLA-G and G17 were significantly higher while PGR levels were significantly lower in the gastric cancer group (all p < 0.001). ROC analysis revealed that the combined model of sHLA-G, PGR, and G17 had the best diagnostic performance (AUC = 0.89, sensitivity 86.90%, specificity 76.52%). Additionally, sHLA-G levels were closely associated with cancer progression, tumor size, lymph node metastasis, and Helicobacter pylori infection, suggesting it may serve as a biomarker for gastric cancer progression.

Conclusion

Serum sHLA-G can serve as an effective biomarker for gastric cancer screening, revealing a better effective diagnostic performance in combination with PGR and G-17. The combination of these biomarkers enhances diagnostic accuracy and may facilitate early diagnosis and risk stratification of gastric cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsEarly Detection of CancerBiomarkers, TumorHLA-G AntigensHumansMaleFemaleAgedRetrospective StudiesROC CurveGastrinsPepsinogen AMiddle AgedPepsinogen CAged, 80 and over

Stichwörter der Autor:innen

DiagnosisGastric cancerGastrin-17PGI/PGII ratioSerum-soluble human leukocyte antigen-G

Substanzen

Biomarkers, TumorHLA-G AntigensGastrinsPepsinogen Agastrin 17Pepsinogen C

Autor:innen und Institutionen

  • General Surgery Department, Hengshui People's Hospital, Hengshui, China.
  • Department of Neurology, Hengshui People's Hospital, Hengshui, China.

Zitieren

APA

Bao, S., Wang, X., & Zhao, J. (2025). Serum-Soluble Human Leukocyte Antigen-G Serves as a Biomarker for Early Gastric Cancer Screening among the Elderly People. Digestive Diseases. https://doi.org/10.1159/000547447

Vancouver

Bao S, Wang X, Zhao J. Serum-Soluble Human Leukocyte Antigen-G Serves as a Biomarker for Early Gastric Cancer Screening among the Elderly People. Digestive Diseases. 2025. doi:10.1159/000547447

BibTeX
@article{Bao2025,
  author = {Bao, Shuangzhen and Wang, Xinying and Zhao, Jiangang},
  title = {Serum-Soluble Human Leukocyte Antigen-G Serves as a Biomarker for Early Gastric Cancer Screening among the Elderly People},
  journal = {Digestive Diseases},
  year = {2025},
  doi = {10.1159/000547447}
}
Kostenlos starten →